Europe – Page 23 – pharmaceutical daily

March 10, 2022 Off

Exscientia and University of Oxford Launch “Xcellomics” Program to Expedite Early-Stage Academic Research and Translate Novel Biology Into Future Drug Discovery

Exscientia and the University of Oxford Target Discovery Institute (Oxford TDI) have announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs.

March 10, 2022 Off

Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology

By Dino Mustafić

Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in…

March 10, 2022 Off

Scenic Biotech Announces $31 Million Financing to Progress Pipeline of Genetic Modifiers in Cancer and Rare Diseases

By Dino Mustafić

Scenic Biotech BV, a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, has closed a Series A financing of ~$31 million (€28 million).

March 10, 2022 Off

Medexprim Appoints Alexandre Blanchot as Business Development Manager

By Dino Mustafić

Medexprim has appointed Alexandre Blanchot as Business Development Manager.

March 10, 2022 Off

Novartis Signs Initial Agreement with Carisma Therapeutics for the Manufacturing of HER 2 Targeted CAR-M Cell Therapy

By Dino Mustafić

Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.

March 10, 2022 Off

NEJM publication of Novartis Kisqali Data Shows Longest Median Overall Survival Ever Reported in HR+/HER2- Advanced Breast Cancer

By Dino Mustafić

The New England Journal of Medicine (NEJM) published data showing the Phase III MONALEESA-2 trial for NovartIs’s Kisqali (ribociclib) plus letrozole demonstrated a statistically significant improvement in overall survival.

March 9, 2022 Off

Thermo Fisher Scientific Extends Collaboration with Symphogen to Advance Biopharmaceutical Discovery and Development

By Author

Thermo Fisher Scientific and Servier’s affiliate Symphogen have announced the continuation of their collaboration to provide biopharmaceutical discovery and development…

March 9, 2022 Off

Novo Nordisk Expands Research Collaboration in Novel Delivery Technologies for Biologic Medicines

By Dino Mustafić

Novo Nordisk has expanded its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH).

March 9, 2022 Off

Lutz Hilbrich Appointed as Senator to the Senate of Economy Europe

By Dino Mustafić

MiGenTra and ProBioGen have announced the appointment of Dr. Lutz Hilbrich, Chief Executive Officer of both companies, as Senator to…

March 9, 2022 Off

SOBI’s and Sanofi’s Haemophilia A Drug Met the Primary and Key Secondary Endpoints

By Dino Mustafić

Swedish Orphan Biovitrum (SOBI) and Sanofi have announced positive top-line results from the pivotal XTEND-1 phase 3 study evaluating the…